Cabaletta Bio Inc Stock

$1.21

2.82% today

Nasdaq, Apr 03, 06:48 pm CET

ISIN

US12674W1099

Symbol

CABA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Cabaletta Bio Inc Stock price

$1.24

-5.58 81.82% 5Y

Nasdaq, Closing price Wed, Apr 02 2025

+0.07 5.98%

ISIN

US12674W1099

Symbol

CABA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$62.92m
Enterprise Value	$-85.44m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	0.94
P/B ratio (TTM) P/B ratio	0.41
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-125.14m
Free Cash Flow (TTM) Free Cash Flow	$-90.43m
Cash position	$163.96m
EPS (TTM) EPS	$-2.34
P/E forward	negative
P/S forward	10.79
EV/Sales forward	negative
Short interest	13.17%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

Cabaletta Bio Inc Stock Analysis

Unlock Scores for Free

??

10 Analysts have issued a Cabaletta Bio Inc forecast:

8x Buy

80%

2x Hold

20%

More details on Analyst Estimates Including Price Targets

10 Analysts have issued a Cabaletta Bio Inc forecast:

Buy

80%

Hold

20%

Analyst Estimates with Stock Price Targets

Financial data from Cabaletta Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	1.71 1.71	27% 27% -
Gross Profit	-1.71 -1.71	27% 27% -
- Selling and Administrative Expenses	25 25	69% 69% -
- Research and Development Expense	97 97	75% 75% -
EBITDA	-123 -123	71% 71% -
- Depreciation and Amortization	1.71 1.71	27% 27% -
EBIT (Operating Income) EBIT	-125 -125	68% 68% -
Net Profit	-116 -116	71% 71% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Cabaletta Bio Inc Stock News

Neutral

GlobeNewsWire

●

3 days ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence presentation in November 2024 with 33 patients enrolled across 56 active clinical trial sites in the U.S. & Europe as of March 14, 2025 – – Clinical and translational data on rese-cel t...

Neutral

Business Wire

●

15 days ago

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), has concluded the Technology Adoption Program (TAP) on its automated cell therapy manufacturing Cell Shuttle™ for resecabtagene autoleucel, (rese-cel, previously known as CABA-201). Rese-cel is the lead clinical candidate in development by Cabaletta Bio, a biotechnolog...

Neutral

GlobeNewsWire

●

about one month ago

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, Mar...

More Cabaletta Bio Inc News

Company Profile

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

Head office	United States
CEO	Steven Nichtberger
Employees	161
Founded	2017
Website	www.cabalettabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now